Needham added Axsome Therapeutics (AXSM) to the firm’s Conviction List while removing Blueprint Medicines (BPMC). Axsome’s lead asset Auvelity should continue to grow in major depressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback